iPS Cells & Regenerative Medicine– category –
-
Texas Children’s Hospital Establishes Cell and Gene Therapy Innovation Hub to Accelerate Development and Expand Access
Texas Children's Hospital USA Overview Texas Children's Hospital has established a new innovation hub to accelerate breakthroughs in cell and gene therapy (CGT). This comprehensive facility centralizes all necessary resources and experti... -
CGT Manufacturers Transform Regulatory Demands into Innovation Drivers: New Strategies for Enhanced Quality and Efficiency
MasterControl USA Overview Cell and gene therapy (CGT) manufacturers are adopting new strategies to leverage stringent regulatory requirements as opportunities for innovation and quality improvement, rather than mere obstacles. Central t... -
RiboX Therapeutics Receives FDA IND Clearance for RXIM002, the First Circular RNA-Based In Vivo CAR Therapy for Autoimmune Cytopenias
BioSpace USA Overview RiboX Therapeutics has received FDA Investigational New Drug (IND) clearance for RXIM002, a circular RNA (circRNA)-based in vivo CAR therapy targeting autoimmune cytopenias. RXIM002 is the first in vivo CAR therapy ... -
RegMedNet Highlights Specialized Partnerships to Overcome Cell Therapy Challenges: New Strategies for Accelerated Commercialization
RegMedNet Unknown Overview RegMedNet's latest 'Cell Therapy Weekly' edition spotlights emerging specialized partnerships aimed at resolving critical challenges in the cell therapy sector. These collaborations focus on streamlining comple... -
CDMO Capacity Crunch Persists in Cell and Gene Therapy Sector: Strategic Partnerships Crucial for Accelerating Innovation
Contract Pharma USA Overview The cell and gene therapy (CGT) sector faces a severe and persistent capacity crunch among Contract Development and Manufacturing Organizations (CDMOs), driven by soaring demand. This bottleneck significantly... -
Children’s Hospital Los Angeles Joins Multi-Center Trial for In Vivo CRISPR Gene Editing Therapy for Sickle Cell Disease
Children's Hospital Los Angeles (CHLA) Facebook USA Overview Children's Hospital Los Angeles (CHLA) has announced its participation in a multi-center clinical trial evaluating a novel CRISPR-based, direct gene editing therapy for sickle ... -
CRISPR and the Dawn of Germline Editing: Curing Hereditary Disease at the Source
Liv Hospital Turkey Overview Germline genome editing, often referred to as 'baby gene editing,' leverages advanced CRISPR technology to offer a potentially curative approach for monogenic diseases at the embryonic stage. While CRISPR's e... -
CRISPR Gene Editing Achieves Clinical Breakthroughs in Sickle Cell Disease Treatment
Liv Hospital Turkey Overview Clinical trials employing CRISPR gene-editing technology for sickle cell disease are reporting highly promising results, significantly reducing severe vaso-occlusive crises and transfusion dependency. Utilizi... -
Investigational CRISPR Therapy Achieves First Clinical Success in Patient with Drug-Resistant E. Coli, Curing Infection
Clinical Trials Arena Unknown Overview A groundbreaking clinical trial has reported the first successful treatment of a patient with multidrug-resistant E. coli using a CRISPR-based therapy. This innovative treatment directly targeted an... -
CRISPR Cancer Therapy 2026: 32 Clinical Trials Underway, Gene-Edited T-Cells Face Efficacy and Off-Target Challenges
Hirschfeld Oncology USA Overview As of 2026, 32 clinical trials are investigating CRISPR-edited immunotherapies for cancer, predominantly focusing on ex vivo gene-edited immune cells. While these therapies generally demonstrate favorable...
